Articles & Insights

Aug 04, 2026

Safety Regulatory

Where The Powder Comes From, And Why The Law Asks

Before a licensed pharmacy can compound from a raw active ingredient, federal law makes it answer one question: who made the powder, and can you prove it. That single question is the whole difference between a regulated supply chain and a package from an anonymous seller. Peppies does not sell peptides, and nothing here is medical advice.

Read article →

Aug 03, 2026

Safety Regulatory

Purity Is Not Sterility, And Nobody Inspects A Mailbox

A certificate of analysis describes a powder. It says nothing about the room the powder was handled in. For anything injected, federal law and the pharmacy rulebook care less about the molecule than about air quality, gowning, and sealed ceiling tiles. That gap is where the grey market's real risk lives. Peppies does not sell peptides.

Read article →

Aug 02, 2026

Bpc 157 Regulatory

Why 40 Amino Acids Decides Whether Something Is A Drug Or A Biologic

A peptide is a short chain of amino acids. Federal regulation draws a hard line at 40 of them: at 40 or fewer you are a drug, above 40 you are a biologic, and the two travel completely different legal roads. That single number is why the compounding fight is about peptides at all, and why it never touches insulin.

Read article →

Aug 01, 2026

Safety Regulatory

What 99 Percent Pure Actually Means on a Peptide Label

A grey-market vial usually arrives with a one-page certificate claiming 99 percent purity, and most buyers read that as a clean bill of health. In peptide chemistry it answers a much narrower question. Here is how these molecules are built, what the missing fraction is made of, and why the one impurity threshold the FDA has written down for synthetic peptides is measured in tenths of a percent. Peppies does not sell peptides.

Read article →

Jul 31, 2026

Safety Regulatory

The Three-Part Test That Decides What A Pharmacy Can Compound

Federal law gives a compounding pharmacy exactly three doors it can walk through to use a raw ingredient, and peptides like BPC-157 do not fit through the first two. That single piece of plumbing explains why a whole advisory committee had to sit down in July and vote. It also explains something more useful: what the law puts on a legal vial, and what an anonymous one has instead.

Read article →

Jul 29, 2026

Safety Regulatory

Australia Is Fighting the Same Vial a Different Way

While a US advisory panel spent last week weighing whether pharmacies should be allowed to compound peptides, Australia's regulator went the other direction and made unapproved peptide products a formal enforcement priority. Two countries, the same unverified vial, two different answers. Here is what each approach reaches, and what neither one reaches on its own.

Read article →

Jul 28, 2026

Safety Regulatory

The Grey Market Runs on Crypto, and Its Own Safety Testing Collapsed

Banks and card processors will not touch grey-market peptides, so the trade moved onto crypto rails and grew past a $100 million annual run rate. The more telling number is the other one: as the market went mainstream, what buyers spent on independent lab testing fell by an estimated 88 percent. Here is why the plumbing is a safety story.

Read article →

Jul 26, 2026

Safety Regulatory

503A vs 503B: Two Compounding Rules, Two Different Fights

The peptide story and the GLP-1 story get talked about as one thing. They are not. They live under two different corners of the same law: Section 503A and Section 503B. Knowing which is which explains why an advisory panel spent two days on peptides, why compounded semaglutide was a shortage story, and why "compounding" is not a single argument.

Read article →

Jul 25, 2026

Safety Regulatory

How to Tell a Licensed Pharmacy From a Grey-Market Seller

An FDA advisory panel just backed a legal, prescription route for several peptides. That pathway only protects you if the pharmacy on the other end is real. Here is a plain-English checklist for telling a state-licensed compounding pharmacy apart from an anonymous online seller, and why the difference is the whole point.

Read article →

Jul 23, 2026

Bpc 157 Regulatory

The Advisory Committee Is Meeting. Here Is What Its Vote Actually Does

The FDA's advisory committee meets July 23-24 to weigh seven peptides for the 503A compounding list. If you are hearing that a vote this week could ban BPC-157 overnight, that is not how the process works. Here is the plain-English version of what a PCAC recommendation is, and what still has to happen after it.

Read article →

Jul 22, 2026

Customs Just Seized Thousands of Peptide Shipments From China

U.S. Customs and Border Protection says it intercepted more than 5,000 unapproved peptide shipments smuggled from China, packed as pre-labeled parcels bound for individual buyers. The seizure is a snapshot of the grey market the FDA is now reviewing, and of why an anonymous overseas vial is the riskiest way to get these products.

Read article →

Jul 22, 2026

The FDA's peptide briefing books are out. Here's what they actually say

One day before the advisory panel meets, the FDA has posted its own scientific reviews of all seven peptides. On every one, staff propose the same answer: not yet.

Read article →

Jul 18, 2026

"Research use only" is a label, not a legal shield

Every grey-market peptide vial carries some version of the same disclaimer. Here is what federal law actually says about it, in plain English.

Read article →

Jul 17, 2026

The peptide review doesn't stop at seven

Most of the attention on next week's FDA panel treats it as one big up-or-down moment. It isn't. The July 23-24 meeting is tranche one of a phased review, and five more peptides are already lined up behind it.

Read article →

Jul 15, 2026

503A vs. 503B: two compounding lists, two different fights

The peptide review and the compounded-Ozempic crackdown are both about "compounding", but they run on two separate legal tracks. Here's how to tell them apart.

Read article →

Jul 12, 2026

Everyone Says "Verified." Almost No One Verifies.

On a grey-market peptide listing, one word does more work than any other: *verified*. "Third-party tested." "COA available." "99% pure." The batch number is right there in the photo. It is the reassurance layer of an unregulated market, and once you see how it is built, you cannot unsee it.

Read article →